12:00 AM
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Pristiq desvenlafaxine: Phase III data

A double-blind, international Phase III trial in 548 patient responders showed that once-daily 50 mg Pristiq met the primary endpoint of increasing time to relapse, defined as HAM-D17 total score of 16, discontinuation due to unsatisfactory efficacy, hospitalization for depression, suicide, or suicide attempt, vs. placebo (p<0.001)....

Read the full 211 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >